Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Effect of Bacillus Subtilis ATCC 122264 Supplementation on Gas Symptoms and Quality of Life in Participants With Functional Bloating

← catalyst calendar

NCT06308146

Sponsored by Kerry Group P.L.C (industry) · KYGA.L — their whole pipeline →. With Nutrasource Pharmaceutical and Nutraceutical Services, Inc..

Phase
Not applicable
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
100actual
Sites
1
Country
Canada

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-25

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2022-04-21actualWhen the study began enrolling
Primary completion2022-10-11actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2022-10-11actualThe whole study's end, after follow-up
First posted2024-03-13actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2024-03-15actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Functional Bloating

Interventions

  • Dietary supplement: Bacillus subtilis ATCC 122264
  • Dietary supplement: Placebo

Primary outcome

what the primary-completion date above is the date OF
Effect on intestinal gas symptoms and quality of life
measured 8 weeks

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · KYGA.L's whole pipeline · Catalyst calendar · Every registered study · What changed